allograft renal transplantation during the period from January 2009 to December 2011，and 45 of the kidney recipientsdeveloped interstitial pneumonia and the incidence rate was 10.34%. Kidney transplant recipients during the period from January 2008 to December 2008 received intravenous ganciclovir during the hospital stay and oral ganciclovirin the post-discharge period. Kidney transplant recipients during the period from January 2009 to December 2011 received oral ganciclovir and trimethoprim

-sulfamethoxazole（SMZ-TMP）in the post-discharge period accordingto the plasma concentration and the level of serum creatinine. When diagnosed with interstitial pneumonia bypulmonary CT，the immunosuppressive drugs of the recipients during the period from January 2008 to December2008 were reduced or withdrew，and corticosteroid therapy，ganciclovir resistant cytomegalovirus（CMV）treatment，combination with the cotrimoxazole antiprotozoal treatment were given. The recipients during the period from January2009 to December 2011 were received regular high-dose corticosteroid and withdrew the immunosuppressive drugs，given ganciclovir resistant CMV treatment with combination of cotrimoxazole antiprotozoal treatment. In the group of recipients during the period from January 2008 to December 2008，35 cases were cured/improved，2 cases died，1 case abandoned treatment and 3 cases developed rejection reaction during the treatment period. In the group ofrecipients during the period from January 2009 to December 2011，45 cases were cured/improved，no case died and 3cases developed rejection reaction during the treatment period. There were a total of 573 patients underwent allograft renal transplantation during the period from 2008 to 2011，among who 183 patients received antibody inductiontherapy including basiliximab or antithymocyte globulin（ATG），and the other 390 patients did not receive. Among 83patients who developed interstitial pneumonia after kidney transplantation，27 patients received antibody inductiontherapy including basiliximab or ATG，while 56 patients did not receive. Conclusions Early discontinuationof immunosuppressive agents and given corticosteroid therapy，ganciclovir resistant CMV treatment，combinationthe cotrimoxazole antiprotozoal treatment and effective nutrition support therapy were effective in the treatmentof interstitial pneumonia after renal transplantation. In addition，under effective medication guide for interstitial pneumonia prevention after renal transplantation，kidney transplant patients' occurrence of interstitial pneumonia was not significantly associated with their use of antibody induction therapy.